We are a UK biotech company focused on the discovery and development of a completely novel class of selective cytotoxic payloads for antibody drug conjugates (ADCs), based on inhibitors of N-myristoyltransferases (NMT) for the treatment of cancer.

Brandon Capital Partners

Sofinnova Partners

Myricx Bio

FUNDING NEWS: We are thrilled to announce our £90m ($114m) series A financing, one of the largest biotech series A in European biotech and the largest in the UK this year. The round was co-led by new investors Novo Holdings and Abingworth. Additional new investors British Patient Capital, Cancer Research Horizons and Eli Lilly and Company also participated alongside founding investors Brandon Capital and Sofinnova Partners.

The series A funds enable us to build out our proprietary N-Myristoyltransferase inhibitor (#NMTi) antibody-drug conjugate (#ADC) payload platform and advance our pipeline of NMTi-ADCs through clinical proof of concept targeting clinically validated tumour-associated antigens. The ADC area is one of the most promising modalities and new payloads are urgently needed. 

Having been a virtual company since spinning out from Imperial College London and The Francis Crick Institute, we will now move to establish laboratory operations in London’s biotech hub and will be expanding our management and R&D teams. 

Welcome to our new investors and thank you to everyone that has contributed to the progress of the company so far, not least our founding scientists Ed Tate, Roberto Solari and Andy Bell. Exciting times ahead.

Read the full release HERE https://lnkd.in/eSu9mP3c

#venturecapital #financing #drugdevelopment #UKbiotech

It was a pleasure meeting BiotechTV new European correspondent Amy Brown and explaining our excitement around the prospects for our #NMTi-ADCs. Great to be financed to take two programs into the clinic and further develop our NMTi payload platform.

🎉 #BIAmember Brandon Capital today announced the launch of their sixth fund with a $270 million initial close to drive #LifeScience innovation ➡️ https://ow.ly/u0QS50S89Kn

The new #Fund will support the growth of 🌏 #Australian and #NewZealand #LifeSciences startups, invest in scale-ups, and expand Brandon Capital’s international presence, particularly in the 📍 #UK, #Europe, and the #USA 🚀

More information in the link above 👆

Our CSO, Francesca Zammarchi, is speaking about our novel NMTi payload platform and pre-clinical efficacy studies for our lead ADCs at the ADC Payload Summit, Boston, MA on May 22nd at 12.30pm. 
#drugdiscovery #oncology #cancer  #antibodydrugconjugates

Overall deal flow in biopharma tapered off in 2023 but the big companies sure know what they want, according to a new report from J.P. Morgan.

Looking forward to seeing investors, partners and industry colleagues next week in San Francisco at #JPM24. Lots of positive progress and potential in the #ADC space, so exciting times ahead.

Euro

Microsoft Exchange Online

Office 365 Mail

Microsoft Azure DNS

GoDaddy DNS

Chairman

Chris Martin

Roberto Solari

Chief Scientific Officer

Francesca Zammarchi

Head of Bioinformatics

Francesco Falciani

COO/ CFO

Julie Mead

Vice President Clinical Development

Robert McLeod

Chief Executive Officer

Robin Carr

Christopher Martin

Lucille Conroy

Michael Bauer

Grant Hawthorne

Chairman, Chief Executive Officer and Co-founder

Zahid Bashir

Chief Medical Officer

Richard Rutter

Head of Biology

Andrew Bell

Chemistry Consultant and Co-founder

Ed Tate

Co-founder and Chairman of the Scientific Advisory Board

United Kingdom Companies With Fewer Than 1000 Employees (Top 10K)

Europe, Middle East, and Africa (EMEA) Biotechnology Companies (Top 10K)

Biotechnology Companies With Fewer Than 1000 Employees (Top 10K)

Life Science Companies

Myricx Bio is a small molecule drug discovery company engaged in developing novel proprietary inhibitors of human N-myristoyl transferase (NMT), primarily focusing on oncology and exploring potential applications across other diseases. NMT is an enzyme that modifies key proteins for cancer cell survival with specific lipids. Myricx Bio is developing a pipeline of ADCs using its NMT inhibitor (NMTi) payload platform to address critical unmet needs in oncology. It shows excellent preclinical efficacy and safety across various solid tumor antigens and cancer cell types.

Abingworth

Novo Holdings

Series A - Myricx Bio

Seed Round - Myricx Bio

London

England

United Kingdom

Europe

European VC Funding Drops To Lowest Quarter In 4 Years, Despite Uptick For German Startups

Myricx Bio appoints Dr. Paolo Paoletti to its Board as Independent Director

Myricx raises £90m after pivot to ADCs for cancer

'Galvanized' by early data, British biotech Myricx secures $114M series A to take ADCs into clinic

Myricx Bio Announces £90m ($114m) Series A Financing to

Myricx raises £90M in Europe’s largest series A for NMT inhibitors

Myricx Bio Raises $115M in Series A to Advance ADC With Lilly and Novo Backing

Lilly and Novo Owner Back UK Biotech Myricx in £90 Million Round

Myricx Bio Raises £90M in Series A Funding

ADC Therapeutics is a biotechnology company focused on the development of antibody-drug conjugates (ADCs) for the treatment of cancer.

ADC Therapeutics

Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) for cancer treatment.

Mersana Therapeutics

Seattle Genetics is a biotechnology company specializing in the development and commercialization of antibody-based therapies for cancer treatment, including antibody-drug conjugates (ADCs).

Seattle Genetics

Myricx Bio is a UK biotech company focused on the discovery and development of a novel class of selective cytotoxic payloads for antibody drug conjugates (ADCs), based on inhibitors of N-myristoyltransferases (NMT) for the treatment of cancer.

news impact assignment basic	general
public peers	general	Jul 9, 2024 7:55 AM	8427adf3
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Jul 9, 2024 9:29 AM	ff444aa8
company summary	general
signals	general
crunchbase trigger	general	Nov 12, 2024 8:36 AM	dd6242ca
crunchbase profile	general	Nov 12, 2024 8:48 AM	d8f75497
li profile	general	Jul 9, 2024 7:55 AM	cd2abd96
translate crunchbase fundingrounds	general	Nov 12, 2024 8:50 AM	d1c3192c
peers	general	Nov 12, 2024 8:36 AM	41856179
news basic	general	Nov 12, 2024 8:36 AM	51d6bade
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:MYRICXBIO

Myricx Bio